Surgical outcomes are less than ideal and recent data will be reviewed on optimal combination of immunotherapy with surgery to improve those outcomes.

The session will provide updated information about former and novel regulatory approvals requiring the use of biomarkers for patient selection to optimal anti-cancer treatments.

The Plenary session highlights abstracts of scientific significance deemed to have the highest merit and greatest impact on radiation oncology research and practice.

The development of LDCT screening for lung cancer was a significant advance; there are patient populations that were not included in the original studies.

Use of tobacco products, marijuana, opioids, herbal supplements and illicit substances is quite common and can have significant impact on safety and efficacy of cancer treatments and pain tolerance.

With the increasing use of cancer immunotherapies for a variety of cancers, including lung cancer, there has been a parallel increase in the toxicity profile across organ systems.

There have been many advances in the systemic therapy for lung cancer. Novel agents carry with them unique toxicities and considerations for multidisciplinary cancer care.

Immunotherapy has become standard of care for all stages of NSCLC. However, there is a gap in knowledge on how to select patients for neoadjuvant immunotherapy followed by surgical resection.